Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Cuts Q3 Spending, Loss on No Revenues

NEW YORK (GenomeWeb News) – Compugen today reported that its third quarter net loss fell 44 percent as the firm cut its R&D and SG&A spending.

The Israeli company reported no revenues for the three-month period ended Sept. 30, compared with revenues of $6,000 for the third quarter of 2008.

Compugen's net loss decreased to $1.9 million, or $.06 per share, from $3.3 million, or $.12 per share, year over year.

The firm's R&D costs declined 37 percent to $1.4 million from $2.3 million, and its SG&A spending fell to $757,000 from $1.3 million year over year.

"The industry interest and collaboration opportunities that we are now seeing for our company exist solely due to the broadly applicable drug and biomarker discovery capability that has been created at Compugen during the past decade," Compugen Co-CEO Martin Gerstel.

As of the end of the third quarter, Compugen had cash, cash equivalents, short-term deposits, and marketable securities of $5.7 million.

In early Tuesday trade on the Nasdaq, Compugen's shares were up less than 1 percent at $2.80.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.